Lyell Immunopharma Inc
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells… Read more
Lyell Immunopharma Inc (LYEL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.087x
Based on the latest financial reports, Lyell Immunopharma Inc (LYEL) has a cash flow conversion efficiency ratio of -0.087x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.58 Million) by net assets ($329.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Lyell Immunopharma Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Lyell Immunopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Lyell Immunopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lyell Immunopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RDC Semiconductor Co Ltd
TWO:3228
|
-0.019x |
|
VIEMED HLTHCARE INC. O.N.
F:VIJ
|
N/A |
|
Mennica Polska S.A.
WAR:MNC
|
0.071x |
|
STHREE PLC LS -01
F:S8T
|
N/A |
|
Rezolve AI PLC
F:O5F
|
N/A |
|
Zhejiang Zhengyuan Zhihui Technology Co Ltd
SHE:300645
|
0.057x |
|
DREAM UNLIMITED A SV
F:50DA
|
N/A |
|
Jiangsu Jibeier Pharmaceutical Co Ltd
SHG:688566
|
0.005x |
Annual Cash Flow Conversion Efficiency for Lyell Immunopharma Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Lyell Immunopharma Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $382.82 Million | $-162.39 Million | -0.424x | -69.73% |
| 2023-12-31 | $654.95 Million | $-163.69 Million | -0.250x | -22.83% |
| 2022-12-31 | $833.25 Million | $-169.56 Million | -0.203x | -49.86% |
| 2021-12-31 | $929.79 Million | $-126.25 Million | -0.136x | +39.36% |
| 2020-12-31 | $718.44 Million | $-160.87 Million | -0.224x | -331.47% |
| 2019-12-31 | $408.06 Million | $39.47 Million | 0.097x | -- |